Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02117817
Title Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

endometrial carcinoma

ovarian cancer

Therapies

Buparlisib + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries


No variant requirements are available.